http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 05 Aug 2026 08:19:28 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Arrowhead+Pharma+%28ARWR%29+PT+Raised+to+%24104+at+Stifel/26870771.html Stifel analyst James Condulis raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $104.00 (from $98.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Arrowhead+Pharma+%28ARWR%29+PT+Raised+to+%24104+at+Stifel/26870771.html Wed, 05 Aug 2026 08:19:28 -0400 ARWR http://www.streetinsider.com/Earnings/Arrowhead+Pharmaceuticals+Inc.+%28ARWR%29+Misses+Q3+EPS+by+16c/26866881.html <p>Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($1.36), $0.16 worse than the analyst estimate of ($1.20). Revenue for the quarter came in at $75.23 million versus the consensus estimate of $52.66 million.</p><p>For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) <a href="http://www.streetinsider.com/ec_earnings.php?q=ARWR">click here</a>.</p> http://www.streetinsider.com/Earnings/Arrowhead+Pharmaceuticals+Inc.+%28ARWR%29+Misses+Q3+EPS+by+16c/26866881.html Tue, 04 Aug 2026 16:26:31 -0400 ARWR http://www.streetinsider.com/Earnings/Arrowhead+Pharmaceuticals+Inc.+%28ARWR%29+Misses+Q3+EPS+by+16c/26866388.html <p>Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($1.36), $0.16 worse than the analyst estimate of ($1.20). Revenue for the quarter came in at $75.23 million versus the consensus estimate of $52.66 million.</p><p>For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) <a href="http://www.streetinsider.com/ec_earnings.php?q=ARWR">click here</a>.</p> http://www.streetinsider.com/Earnings/Arrowhead+Pharmaceuticals+Inc.+%28ARWR%29+Misses+Q3+EPS+by+16c/26866388.html Tue, 04 Aug 2026 16:11:37 -0400 ARWR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ARROWHEAD+PHARMACEUTICAL++For%3A+Jun+30/26865924.html si-local-file:///var/storage/secattach/20260804/26865924.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ARROWHEAD+PHARMACEUTICAL++For%3A+Jun+30/26865924.html Tue, 04 Aug 2026 16:03:00 -0400 ARWR O.01522756 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ARROWHEAD+PHARMACEUTICAL++For%3A+Jun+30/26865924.html si-local-file:///var/storage/secattach/20260804/26865924.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ARROWHEAD+PHARMACEUTICAL++For%3A+Jun+30/26865924.html Tue, 04 Aug 2026 16:03:00 -0400 ARWR O.01522756 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ARROWHEAD+PHARMACEUTICAL++For%3A+Aug+04/26865942.html si-local-file:///var/storage/secattach/20260804/26865942.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ARROWHEAD+PHARMACEUTICAL++For%3A+Aug+04/26865942.html Tue, 04 Aug 2026 16:03:00 -0400 ARWR O.01522756 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ARROWHEAD+PHARMACEUTICAL++For%3A+Aug+04/26865942.html si-local-file:///var/storage/secattach/20260804/26865942.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ARROWHEAD+PHARMACEUTICAL++For%3A+Aug+04/26865942.html Tue, 04 Aug 2026 16:03:00 -0400 ARWR O.01522756 http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Press+Releases/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html <p class="bwalignc"> - Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&amp;esheet=54583373&amp;newsitemid=20260804998802&amp;lan=en-US&amp;anchor=Arrowhead+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=2766e0b8e8cb027612a4e98eccdb0488" shape="rect">Arrowhead Pharmaceuticals, Inc.</a> (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. </p><p> “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is http://www.streetinsider.com/Business+Wire/Arrowhead+Pharmaceuticals+Reports+Fiscal+2026+Third+Quarter+Results/26865840.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/FDA/Arrowhead+buys+FDA+priority+review+voucher+for+plozasiran+sNDA/26865787.html <p>Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has signed an agreement to acquire a U.S. Food and Drug Administration Rare Pediatric Disease Priority Review Voucher from an undisclosed third party, according to a press release from the company.</p> <p>Arrowhead intends to use the voucher for a planned Supplemental New Drug Application for plozasiran, which the company anticipates submitting before the end of 2026. The sNDA would seek to expand the approved indication to include patients with severe hypertriglyceridemia, a condition that raises the risk of acute pancreatitis.</p> <p>A Priority Review designation reduces the FDA's target review period to six months, compared to 10 months http://www.streetinsider.com/FDA/Arrowhead+buys+FDA+priority+review+voucher+for+plozasiran+sNDA/26865787.html Tue, 04 Aug 2026 16:00:17 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518 http://www.streetinsider.com/FDA/Arrowhead+buys+FDA+priority+review+voucher+for+plozasiran+sNDA/26865787.html <p>Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has signed an agreement to acquire a U.S. Food and Drug Administration Rare Pediatric Disease Priority Review Voucher from an undisclosed third party, according to a press release from the company.</p> <p>Arrowhead intends to use the voucher for a planned Supplemental New Drug Application for plozasiran, which the company anticipates submitting before the end of 2026. The sNDA would seek to expand the approved indication to include patients with severe hypertriglyceridemia, a condition that raises the risk of acute pancreatitis.</p> <p>A Priority Review designation reduces the FDA's target review period to six months, compared to 10 months http://www.streetinsider.com/FDA/Arrowhead+buys+FDA+priority+review+voucher+for+plozasiran+sNDA/26865787.html Tue, 04 Aug 2026 16:00:17 -0400 A.06822034 A.17150087 A.60012004 ARWR O.01304637 O.01522756 O.20026344 O.34929518